There’s good news in 2026 for seniors enrolled in Medicare Part D who rely on the priciest prescription drugs: 10 high-cost ...

Savings for Part D and Advantage enrollees depend largely on which plan they’re enrolled in, as not all plans are the same.

Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...

Beginning this year, Medicare's new negotiated drug prices could cut prescription costs in half for millions of seniors, a ...

Data from the TRANSITION study presented today at the European Society of Cardiology (ESC) Congress in Munich, Germany has shown that Entresto ® (sacubitril ...

Novartis has held high hopes for cardiovascular med Entresto, pegging peak sales at $5 billion. Now, a major trial setback is hurting the drug's prospects, but Novartis is trying to looking at the ...

Update 3:48pm: Adds Novartis comment on appeal, updates shares. Novartis (NYSE:NVS) lost a patent ruling related to its blockbuster heart failure drug Entresto. Novartis ADRs fell 3.4%. A court found ...

Novartis AGNVS announced results from a post-hoc analysis from the PARADIGM-HF trial on cardiovascular drug Entresto. The results were published in JAMA Cardiology. The results demonstrated that ...

For millions of Medicare enrollees, the biggest changes from Washington may soon be felt not in paperwork or policy language, but at the pharmacy counter. A new study from AARP su ...

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued on ...

The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function ...

Novartis had hoped Entresto could find itself yet another niche, this time in patients who’d had a heart attack. But in late April, a large study found the heart failure drug couldn’t quite top widely ...